COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment ...
The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. Skytrofa ® ...
COPENHAGEN, Denmark, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new ...
The approval was based on data from the phase 3 heiGHt trial that assessed Skytrofa in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. The Food and Drug Administration has ...
SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1] "We are delighted to have secured TGA ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the first once-weekly formulation of somatropin for children with growth hormone deficiency, ...
- Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransCon TM hGH - Initial findings from research on comorbidities associated with adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback